Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Ibrutinib Plus Rituximab for Rare Blood Cancer

Aug 27, 2018, 09:42 AM
URL:
On August 27, AbbVie announced that the FDA has approved ibrutinib (Imbruvica) (Pharmacyclics, LLC) plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia (WM), a rare and incurable type of non-Hodgkin's lymphoma (NHL). This approval represents the first and only chemotherapy-free combination treatment specifically indicated for the disease.

Read the full AbbVie corporate press release here.

Posted 8/27/2018

Leave a comment